

RECEIVED  
CENTRAL FAX CENTER  
SEP 05 2006

Attorney Docket No.: 5676.210-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Olsen et al.

Confirmation No: 3283

Serial No.: 10/730,454

Group Art Unit: 1639

Filed: December 8, 2003

Examiner: S. Liu

For: Low Allergenic Protein Variants

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This paper is filed in response to the Office Action mailed July 28, 2006 that made restriction and election of species requirements. Applicants were requested to elect one of the following 15 designated groups:

Groups 1-13 – Claims 27 and 28 drawn to protein variants, wherein each group is drawn to a single sequence identifier from SEQ ID NOs: 88-99;

Group 14 – claims 29-33 drawn to DNA constructs; and

Group 15 – claim 34 drawn to methods of producing a protein variant.

The Office also requested that Applicants elect a single species for each of the following:

- A. range of reduced immunogenicity;
- B. species of host cell; and
- C. species of protein.

In response to these requirements, Applicants hereby elect with traverse the invention of Group 1, wherein the sequence identifier is SEQ ID NO: 88, and the following species:

- A. the immunogenicity of the protein variant is below 75% of the immunogenicity of the parent protein;
- B. the host cell is a bacterium;
- C. the protein is an enzyme.

Claims 27 and 28 read on the elected species. Applicants hereby reserve the right to file continuing applications directed to the nonelected subject matter.


Applicants request clarification of the restriction requirement. Although claims 22-34 are pending in the instant application, claims 22-26 were not indicated as belonging to any group.

Instead, the Office stated that "Claim 22 link(s) inventions of Groups 1 to 13. The restriction requirement among the linked inventions is subject to the nonallowance of the linking claim(s), claim 22. Claims 23-26 and 28 are dependent on Claim 22 and are generic to Groups 1-13. Upon the allowance of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application.

Applicants request that the Office confirm that claims 22-26 will be examined with the elected invention, i.e., Group 1.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,



Elias J. Lambiris, Reg. No. 33,728  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097

Date: September 5, 2006